0000899243-17-007841.txt : 20170316
0000899243-17-007841.hdr.sgml : 20170316
20170316200041
ACCESSION NUMBER: 0000899243-17-007841
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170314
FILED AS OF DATE: 20170316
DATE AS OF CHANGE: 20170316
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZOGENIX, INC.
CENTRAL INDEX KEY: 0001375151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205300780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5858 HORTON STREET, #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 550-8300
MAIL ADDRESS:
STREET 1: 5858 HORTON STREET, #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: ZOGENIX INC
DATE OF NAME CHANGE: 20060911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galer Bradley S.
CENTRAL INDEX KEY: 0001594565
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34962
FILM NUMBER: 17696156
MAIL ADDRESS:
STREET 1: C/O ZOGENIX, INC.
STREET 2: 12400 HIGH BLUFF DR., SUITE 650
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-03-14
0
0001375151
ZOGENIX, INC.
ZGNX
0001594565
Galer Bradley S.
C/O ZOGENIX, INC.
5858 HORTON STREET, STE. 455
EMERYVILLE
CA
94608
0
1
0
0
EVP/Chief Medical Officer
Stock Option (Right to Buy)
10.20
2017-03-14
4
A
0
60000
0.00
A
2027-03-13
Common Stock
60000
60000
D
Restricted Stock Units
2017-03-14
4
A
0
10000
0.00
A
2022-03-13
Common Stock
10000
10000
D
The option was granted on March 14, 2017 and vests in a series of forty-eight (48) successive, equal monthly installments beginning on April 14, 2017, subject to the reporting person's continued employment with the Company on each vesting date.
Each restricted stock unit ("RSU") represents a contingent right to receive one share of ZGNX common stock.
The RSUs shall vest upon the approval by the U.S. Food and Drug Administration of the Company's New Drug Application for ZX008, provided such approval occurs within five years following the grant date, subject to the option recipient's continuous service to the Company on such vesting date.
/s/ Thomas Doyle, Attorney-in-fact
2017-03-16